干细胞领域3件事:新概念股、建最大医院、设首个奖项
2015/12/21
干细胞研究是近年来医学前沿重点发展领域,给某些疑难疾病的治疗提供了希望。本文带大家回顾干细胞领域3件事:汉氏联合挂牌新三板、上海筹建最大干细胞医院、全球干细胞和再生医学领域首个专项奖项设立。


干细胞研究是近年来医学前沿重点发展领域,给某些疑难疾病的治疗提供了希望。据悉,2009 年,中国干细胞产业收入约为 20 亿元,2013 年已经超过 100 亿元,预计到 2015 将达到 300 亿,年复合增长率超过 50%。

目前,我国已形成近百家不同规模的干细胞公司,从事干细胞领域相关技术的研发、干细胞库的建立和干细胞及相关产品的应用;A股市场干细胞相关公司包括中源协和、冠昊生物等,新三板有赛莱拉、天晴干细胞、顺昊生物等。此外,还有一批此前未涉及干细胞领域的公司也在积极布局,包括银河投资、南华生物等。

公司动向

干细胞又出新股,汉氏联合挂牌新三板

近日,新三板干细胞板块再添新军。12月11日,北京汉氏联合生物技术股份有限公司在全国中小企业股份转让系统(即新三板)成功挂牌,股票简称“汉氏联合”。

据悉,汉氏联合设立于2007年,主要从事胎盘干细胞采集和存储服务、干细胞相关美容抗衰老产品和干细胞药物研发;同时拥有包括广东、浙江、福建、贵州和山东等地的12家子公司。

当日,汉氏联合转让620万股(发行价格为9.1元每股),募资5642万元。汉氏联合董事长韩忠朝教授是中国干细胞产业化领军人物,法国国家技术科学院和法国国家医学科学院两院院士,发表科学论文470余篇,拥有发明专利20余项。

产业动向

上海筹建最大干细胞医院

根据Visiongain提供的市场调研数据,预计到2016年,国内干细胞产业的市场规模将达千亿元。截至2015年11月26日,全球范围内干细胞临床试验共计5240项,美国独占2919项,其中有227项进入三期临床试验。而中国仅有257项,且大多处于停滞或“流产”状态。

继2015年上海投入巨资打造干细胞产业基地后;日前,据澎湃新闻报道,上海正在着手筹建全球最大的干细胞医院,目前选址已经确定位于上海市嘉定区,计划于2016年开工。上海交通大学附属瑞金医院北院、江苏省血液研究所等血液病治疗的权威医疗机构,都已与中国干细胞集团签订了框架协议,将为医院建设提供技术支持。  

时事动向

全球干细胞和再生医学领域首个专项奖项

12月12日,国际权威学术期刊美国《科学》杂志与北大博雅控股集团在京联合发起设立“博雅•科学干细胞与再生医学杰出贡献奖”,旨在鼓励全球生命科技领域尤其是干细胞和再生医学领域的技术与应用创新。

据介绍,该奖项是第一个由中国企业与国际科学界具有高度影响力的机构共同设立的全球性奖项。《科学》杂志社长肯特•安德森对该奖项推进全球干细胞研究和临床应用的积极作用表示肯定,他表示将利用《科学》杂志的全球影响力组织一支国际性的专业评选委员会,用于评选该领域的重要贡献者。

此外,值得注意的是,10月27日,停牌两个多月的新日恒力公告了其重大资产购买报告书,公司拟以15.66亿元收购许晓椿、北京明润、杭州茂信等合计持有的博雅干细胞80%股权。博雅干细胞实际控制人许晓椿原持有博雅干细胞80%股权,交易完成后,其持股比例将降为14.17%。

所有文章仅代表作者观点,不代表本站立场。如若转载请联系原作者。
查看更多
  • Cell-free DNA Analysis for Noninvasive Examination of Trisomy

    Background Cell-free DNA (cfDNA) testing for fetal trisomy is highly effective among high-risk women. However, there have been few direct, well-powered studies comparing cfDNA testing with standard screening during the first trimester in routine prenatal populations. Methods In this prospective, multicenter, blinded study conducted at 35 international centers, we assigned pregnant women presenting for aneuploidy screening at 10 to 14 weeks of gestation to undergo both standard screening (with measurement of nuchal translucency and biochemical analytes) and cfDNA testing. Participants received the results of standard screening; the results of cfDNA testing were blinded. Determination of the birth outcome was based on diagnostic genetic testing or newborn examination. The primary outcome was the area under the receiver-operatingcharacteristic curve (AUC) for trisomy 21 (Down’s syndrome) with cfDNA testing versus standard screening. We also evaluated cfDNA testing and standard screening to assess the risk of trisomies 18 and 13. Results Of 18,955 women who were enrolled, results from 15,841 were available for analysis. The mean maternal age was 30.7 years, and the mean gestational age at testing was 12.5 weeks. The AUC for trisomy 21 was 0.999 for cfDNA testing and 0.958 for standard screening (P=0.001). Trisomy 21 was detected in 38 of 38 women (100%; 95% confidence interval [CI], 90.7 to 100) in the cfDNA-testing group, as compared with 30 of 38 women (78.9%; 95% CI, 62.7 to 90.4) in the standard-screening group (P=0.008). False positive rates were 0.06% (95% CI, 0.03 to 0.11) in the cfDNA group and 5.4% (95% CI, 5.1 to 5.8) in the standard-screening group (P<0.001). The positive predictive value for cfDNA testing was 80.9% (95% CI, 66.7 to 90.9), as compared with 3.4% (95% CI, 2.3 to 4.8) for standard screening (P<0.001). Conclusions In this large, routine prenatal-screening population, cfDNA testing for trisomy 21 had higher sensitivity, a lower false positive rate, and higher positive predictive value than did standard screening with the measurement of nuchal translucency and biochemical analytes. (Funded by Ariosa Diagnostics and Perinatal Quality Foundation; NEXT ClinicalTrials.gov number, NCT01511458.)

    展开 收起
发表评论 我在frontend\modules\comment\widgets\views\文件夹下面 test